drugset / Trial / NCT01481883

Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?

NCT01481883

Phase 4 Completed 13 enrolled The Alfred
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this project is to investigate the effect of Raloxifene 120mg in men with schizophrenia. This trial will adopt a 12 week randomised controlled model. Hypotheses 1: That the men receiving adjunctive selective estrogen receptor modulators (SERM) will have a significantly greater reduction in psychosis symptoms over the course of the study than men receiving adjunctive placebo. Hypotheses 2: That the men receiving adjunctive SERM will have a significantly greater improvement in cognitive function than men receiving adjunctive placebo

Timeline

Start
2012-01
Primary completion
2019-01
Completion
2019-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Raloxifene Other / unclassified 120 mg Oral